Persistent symptoms may predict greater lung function decline in patients with asthma. As part of the ALEC study (EU Horizon 2020 grant #633212), we evaluated FEV1/FVC decline over 10 years in adult asthmatics by disease control and daily ICS use. In the ECRHS II study (1999-2002, baseline), 440 subjects (aged 29-55) with a physician-diagnosed current asthma were classified as well-controlled (non-daily ICS use, n=126; daily ICS use, n=19), partially controlled (145; 33) or uncontrolled (72; 45) patients (GINA 2006). The annual change in pre-bronchodilator FEV1/FVC ratio (%/year) between the ECRHS II and ECRHS III (2010-2013) was computed adjusting for gender, age, smoking habits, BMI and total IgE (>100 kU/L) by a 2-level random-intercept linear model (centre: level 2 unit). On average, patients had a lower FEV1/FVC ratio at baseline according to decreased levels of asthma control (from 79.4 to 73.2%; p<0.001). Compared to well-controlled patients with non-daily ICS use, uncontrolled asthmatics taking daily ICS had 0.14 (95%CI: -0.03, 0.30) %/year additional decline in FEV1/FVC ratio. If history of hospitalizations/ED visits for breathing problems [during the years between the ECRHS I (1991-1993) and ECRHS II] was used as a marker of poor control, uncontrolled asthmatics using daily ICS had 0.42 (95%CI: 0.19, 0.65) %/year additional decline in FEV1/FVC ratio, compared to well-controlled patients who reported non-daily ICS use and no past hospital contacts (p-value for interaction: 0.034). Adults with uncontrolled asthma have greater decline in FEV1/FVC ratio compared to well-controlled subjects even if they report daily ICS use. Those in contact with the hospital seem to be at particular risk of greater decline.
Asthma control and decline in FEV1/FVC ratio over 10 years in adults
Accordini, S;Cazzoletti, L;Corsico, A;Portas, L;Marcon, A;
2018-01-01
Abstract
Persistent symptoms may predict greater lung function decline in patients with asthma. As part of the ALEC study (EU Horizon 2020 grant #633212), we evaluated FEV1/FVC decline over 10 years in adult asthmatics by disease control and daily ICS use. In the ECRHS II study (1999-2002, baseline), 440 subjects (aged 29-55) with a physician-diagnosed current asthma were classified as well-controlled (non-daily ICS use, n=126; daily ICS use, n=19), partially controlled (145; 33) or uncontrolled (72; 45) patients (GINA 2006). The annual change in pre-bronchodilator FEV1/FVC ratio (%/year) between the ECRHS II and ECRHS III (2010-2013) was computed adjusting for gender, age, smoking habits, BMI and total IgE (>100 kU/L) by a 2-level random-intercept linear model (centre: level 2 unit). On average, patients had a lower FEV1/FVC ratio at baseline according to decreased levels of asthma control (from 79.4 to 73.2%; p<0.001). Compared to well-controlled patients with non-daily ICS use, uncontrolled asthmatics taking daily ICS had 0.14 (95%CI: -0.03, 0.30) %/year additional decline in FEV1/FVC ratio. If history of hospitalizations/ED visits for breathing problems [during the years between the ECRHS I (1991-1993) and ECRHS II] was used as a marker of poor control, uncontrolled asthmatics using daily ICS had 0.42 (95%CI: 0.19, 0.65) %/year additional decline in FEV1/FVC ratio, compared to well-controlled patients who reported non-daily ICS use and no past hospital contacts (p-value for interaction: 0.034). Adults with uncontrolled asthma have greater decline in FEV1/FVC ratio compared to well-controlled subjects even if they report daily ICS use. Those in contact with the hospital seem to be at particular risk of greater decline.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.